A "homing device" will enhance current prostate cancer detection and treatment of the first disease targeted. A team of researchers at Purdue University has been synthesizing a molecule that discover and suppress prostate cancer cells and has created several imaging and drug therapies that can link between these molecules and transported as cargo.
An application that digunaklan radio imaging observation of the body is expected to enter into medical trials this fall, and applications of optical imaging is used to measure the cell - in prostate cancer cells in blood samples already exist in the clinical trial. Philip Low, a prominent professor at the Ralph C. Corley Biochemistry who led this team, said a targeted treatment may be more effective in the treatment of cancer and greatly reduces the harmful side effects associated with treatment of end - the end of this.
"Right now there are no drugs - drugs that are available to treat prostate cancer that on target, which means they are spread everywhere in the body and only against tumors only, and quite toxic to the patient," said Low, a member of the Purdue Cancer Center. "With the ability to target only cancer cells, we can eliminate toxic side effects of treatment. In addition, the ability to target only cells - cancer cells can improve cancer imaging to diagnose disease, determine if it has spread or respond to such treatment. "
Prostate cancer is the most common cancer, other than skin cancer, and is the second cancer cause of cancer death in the men - men in America, according to the American Cancer Society. It is estimated that about 192.280 new cases will be diagnosed and 27.360 men - men will die from prostate cancer in the United States this year.
The team created a molecule Law patch prostate specific membrane antigen, or PSMA, a membrane protein found on more than 90 percent of all prostate cancers. It is also found in blood vessels of most solid tumors and may provide a way to cut the blood supply of tumors, said Low.
"Most of the drugs - new drugs have been designed to destroy the vasculature of solid tumors, and if they can be connected with this new molecular targeting, we can have two branches to attack prostate cancer," he said. "We do not just kill prostate cancer cells directly, but we can also destroy vasculatur that feed the tumor." They also have the potential for targeting molecules for use in attacking vasculatur of solid tumors in other cancer types, said Low.
Two papers that describe in detail the work of Purdue team published on June 1 in Molecular Pharmaceutics. Endocyte Inc.. finance this work. Data from experimental animal studies the team showed that an ability to eliminate cells - in human prostate cancer cells in mice with toxin levels did not provide evidence that occurred simultaneously in normal tissue. Sumith Kularatne, one graduate department of chemistry at Purdue and author of the first two papers, comparing the molecular targeting of "homing device".
"This molecule acts like a homing device for prostate cancer," he said. "PSMA, which is found only on cells - prostate cancer cells and tumor blood vessels, which acts as a homing signal to target molecules. Cargo molecules and lead to cancerous tissue, leaving healthy jarringan harmless. "
When these molecules reach the PSMA protein, it will be attached to it. These molecules are designed with a specific form according to the same protein as a key in the lock, said Kularatne. This molecule and its cargo and brought into these cells with proteins as walking through its normal cycle. Low in the year 1995 to develop a method similar to infiltrate cells - cancer cells by attaching a treatment for vitamin folate, which is where most cancers will be consumed quickly. This method provides a way in "Trojan Horse" for the treatment of large molecules which otherwise can get into the cells - cancer cells. Low inspired to find a similar way to target prostate cancer, which tiidak same taste of folate, she said.
A clinical trial of radio imaging applications is expected to begin at the Indiana University Medical Center this fall through a collaboration between the Purdue Cancer Center and Indiana University Cancer Center with additional support from Endocyte Inc..
An imaging radio equipment that is connected to the target molecule is injected into the prostate cancer patients and the drawing will be taken by using a special camera detects the radio yamng activities. The pictures will show you where the cancer is to facilitate the physician determine if this has been dimetastasiskan, or spread, to other areas anywhere in the body. It also helps the doctors to decide the best car care, said Low.
Nowadays there is only one radio imaging tool for prostate cancer which was approved by the Food and Drug Administration. "The ability of imaging currently available for prostate cancer is very low," said Low. "Imaging devices are limited due to their large size, which is difficult to find in a solid tumor. Also in finding out who reside in the target cancer cells and can only mark the cells - cells that were injured as opposed to separate cells - cancer cells that grow very active. "
The combination of molecules that become targets and radio imaging tool designed by the Low group of more than 150 times smaller than existing equipment and have an easier penetration through a solid tumor to reach all the cells - the cells inside, he said. It also has the advantage of targeting an area exposed to PSMA on the cells - cancer cells outside.
What already exists in the clinical trial is an optically imaging applications include placing dye molecules fluorescen against targets and percampurannya with blood samples from a patient. Injected cells - in the example of prostate cancer cells fluoresce and easily estimate in helping to diagnose patients with prostate cancer. The researchers are also investigating whether this can be used to evaluate the response of a patient to therapy, said Low.
Research group mempolakan Low molecular targets after the appearance of a natural molecule that strongly bound to the PSMA, is called incense. Some changes needed to make a homing molecule that according to the devices and the transport vehicle, said Kularatne. The team is creating an area on a molecule that will connect various devices imaging or therapy that will bring them as cargo and creates a distance that would loosen regulatory molecule so that its cargo will not save them from packing into the appropriate location of binding. This spacer is also designed to enhance the binding of target molecules to PSMA.
0 comments:
Post a Comment